Author

T. Yasui

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Five-Year Clinical Outcomes Following Nephrectomy for Renal Cell Carcinoma: Evidence From a Nationwide Japanese Surgical Registry.

OBJECTIVES To characterize mid-term oncological outcomes after nephrectomy for renal cell carcinoma (RCC) in Japan using the National Clinical Database (NCD). METHODS We retrospectively analyzed patients with RCC who underwent nephrectomy between April and December 2018 and had at least 5 years of follow-up recorded...

R. Mizuno, Kyoko Yamamoto, Hiroyuki Yamamoto et al. · International journal of uro... · 0 citations

Open access Oct 2026

Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features....

Misato Tomita, Y. Tasaki, S. Hamamoto et al. · Cancer Medicine · 0 citations

Open access Oct 2026

Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis

Immune‐related adverse events (irAEs) frequently occur during combination immune checkpoint inhibition. However, their prognostic impact may vary according to organ involvement and severity. In this study, we exploratorily evaluated whether severe non‐endocrine irAEs represent a temporally distinct and prognostically u...

Y. Tasaki, Kazumasa Sato, S. Hamamoto et al. · Cancer Medicine · 0 citations